Immix Biopharma, a clinical-stage biopharmaceutical company, filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct the date of the independent auditor's report. The company reported a net loss of $29.4 million for the year ended December 31, 2025, an increase from $21.7 million in 2024, contributing to an accumulated deficit of $104.5 million. Cash and cash equivalents significantly increased to $93.9 million as of December 31, 2025, from $17.7 million in 2024, largely due to successful equity financings. Total assets grew to $104.8 million in 2025 from $22.9 million in 2024, while total liabilities increased to $11.0 million from $9.7 million. Research and development expenses rose to $16.3 million in 2025 from $11.3 million in 2024, reflecting ongoing clinical activities. General and administrative expenses also increased to $13.7 million in 2025 from $11.4 million in 2024. The company completed multiple capital raises in 2025, including an At-The-Market (ATM) offering yielding $4.4 million, a private placement generating $9.3 million, and an underwritten public offering raising $93.7 million. Immix Biopharma was awarded an $8 million grant from the California Institute for Regenerative Medicine (CIRM) in July 2024, receiving $2.8 million in 2025 and $1.9 million in 2024, with $3.4 million remaining. The Nexcella, Inc. subsidiary, Immix's cell therapy division, merged into the company in May 2024.